Development

Lilly reports Foundayo's share of new pill patients

development2026-09-22biotech

Claim

The issue reports Lilly's claim that Foundayo accounts for one third of new pill patients; the newsletter does not further specify the population.

Reported metric: a third

Reporting date: (not necessarily the event date)

Sources

Attribution and reporting linked by this record; links do not imply independent verification.

Indexed from the September 22 newsletter. Linked-source claims have not been independently verified.

Knowledge graphopen in browser →

Reported in
Actor
Referenced by

Cite or correct this record

Suggest a correction — opens a GitHub draft for you to review and submit.